Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide | Zendy

Adriana M. Herrera | Zendy; Mary Ellen Vajravelu | Zendy; Stephanie Givler | Zendy; Lauren Mitteer | Zendy; Catherine M. Avitabile | Zendy; Katherine Lord | Zendy; Diva D. De León | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide

Author(s) -

Adriana M. Herrera,

Mary Ellen Vajravelu,

Stephanie Givler,

Lauren Mitteer,

Catherine M. Avitabile,

Katherine Lord,

Diva D. De León

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-01613

Subject(s) - diazoxide , hyperinsulinism , congenital hyperinsulinism , medicine , pediatrics , adverse effect , insulin , insulin resistance

Diazoxide, the only U.S. Food and Drug Administration-approved drug to treat hyperinsulinemic hypoglycemia, has been associated with several adverse events, which has raised concerns about the safety of this drug. Existing reports are limited to small studies and case reports.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research